BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15768028)

  • 1. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
    Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
    Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
    Towne C; Aebischer P
    Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
    Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
    Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
    Jiang HZ; Wang SY; Yin X; Jiang HQ; Wang XD; Wang J; Wang TH; Qi Y; Yang YQ; Wang Y; Zhang CT; Feng HL
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.
    Towne C; Raoul C; Schneider BL; Aebischer P
    Mol Ther; 2008 Jun; 16(6):1018-25. PubMed ID: 18414477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model.
    Saito Y; Yokota T; Mitani T; Ito K; Anzai M; Miyagishi M; Taira K; Mizusawa H
    J Biol Chem; 2005 Dec; 280(52):42826-30. PubMed ID: 16221675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS.
    Haenggeli C; Julien JP; Mosley RL; Perez N; Dhar A; Gendelman HE; Rothstein JD
    Neurobiol Dis; 2007 Apr; 26(1):146-52. PubMed ID: 17276077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
    Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
    Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amyotrophic lateral sclerosis: recent insights from transgenic animal models with SOD1 mutations].
    Aoki M
    Rinsho Shinkeigaku; 2004 Nov; 44(11):788-91. PubMed ID: 15651292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice.
    Guillot S; Azzouz M; Déglon N; Zurn A; Aebischer P
    Neurobiol Dis; 2004 Jun; 16(1):139-49. PubMed ID: 15207271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
    Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
    Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 18. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
    Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
    Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice.
    Locatelli F; Corti S; Papadimitriou D; Fortunato F; Del Bo R; Donadoni C; Nizzardo M; Nardini M; Salani S; Ghezzi S; Strazzer S; Bresolin N; Comi GP
    Ann Neurol; 2007 Jul; 62(1):81-92. PubMed ID: 17503505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.